Form 8-K - Current report:
SEC Accession No. 0001493152-24-051196
Filing Date
2024-12-23
Accepted
2024-12-23 07:35:12
Documents
18
Period of Report
2024-12-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 57354
2 ex4-1.htm EX-4.1 50420
3 ex10-1.htm EX-10.1 150600
4 ex10-2.htm EX-10.2 70854
5 ex99-1.htm EX-99.1 11603
  Complete submission text file 0001493152-24-051196.txt   635574

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cing-20241220.xsd EX-101.SCH 3781
7 XBRL DEFINITION FILE cing-20241220_def.xml EX-101.DEF 30042
8 XBRL LABEL FILE cing-20241220_lab.xml EX-101.LAB 36718
9 XBRL PRESENTATION FILE cing-20241220_pre.xml EX-101.PRE 27065
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5714
Mailing Address 1901 W. 47TH PLACE KANSAS CITY KS 66205
Business Address 1901 W. 47TH PLACE KANSAS CITY KS 66205 (913) 942-2300
Cingulate Inc. (Filer) CIK: 0001862150 (see all company filings)

EIN.: 863825535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40874 | Film No.: 241569881
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)